Case Reports
doi: 10.1016/j.ctarc.2021.100377.
Epub 2021 Apr 20.
Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion
Affiliations
- PMID: 33945921
- DOI: 10.1016/j.ctarc.2021.100377
Item in Clipboard
Case Reports
Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion
Cancer Treat Res Commun.
2021.
Free article
Abstract
Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation.
Keywords: BRAF; Crizotinib; ROS1; Resistance.
Copyright © 2021. Published by Elsevier Ltd.
Similar articles
-
Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.Int J Mol Sci. 2021 Nov 28;22(23):12867. doi: 10.3390/ijms222312867. Int J Mol Sci. 2021. PMID: 34884672 Free PMC article. Review.
-
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.Oncologist. 2021 Dec;26(12):e2115-e2119. doi: 10.1002/onco.13979. Epub 2021 Nov 9. Oncologist. 2021. PMID: 34516041 Free PMC article.
-
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.Drugs. 2019 Aug;79(12):1277-1286. doi: 10.1007/s40265-019-01164-3. Drugs. 2019. PMID: 31313100 Review.
-
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11. Cancer Sci. 2018. PMID: 30053332 Free PMC article.
-
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25. J Thorac Oncol. 2018. PMID: 29704675
Cited by
-
Progress of non-small-cell lung cancer with ROS1 rearrangement.Front Mol Biosci. 2023 Dec 22;10:1238093. doi: 10.3389/fmolb.2023.1238093. eCollection 2023. Front Mol Biosci. 2023. PMID: 38187090 Free PMC article. Review.
-
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.Int J Mol Sci. 2023 Nov 5;24(21):15981. doi: 10.3390/ijms242115981. Int J Mol Sci. 2023. PMID: 37958963 Free PMC article. Review.
-
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.JCI Insight. 2023 Dec 22;8(24):e173688. doi: 10.1172/jci.insight.173688. JCI Insight. 2023. PMID: 37917191 Free PMC article.
-
Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report.Cancer Manag Res. 2022 Nov 15;14:3175-3179. doi: 10.2147/CMAR.S387211. eCollection 2022. Cancer Manag Res. 2022. PMID: 36411743 Free PMC article.
-
The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.Front Oncol. 2022 Jul 13;12:882940. doi: 10.3389/fonc.2022.882940. eCollection 2022. Front Oncol. 2022. PMID: 35912223 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
